Crucell to Concentrate Research and Development in Leiden, The Netherlands
According to Crucell, the decision to concentrate R&D in Leiden has been made to increase efficiency in R&D spending and will result in a reduction in the number of staff employed. Due to the suspension in July 2006 of Aerugen®, the vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, there are fewer projects requiring development support at Bern. This restructuring shall result in the reduction of approximately 60 positions, mainly in Bern.
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.